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ABSTRACT
Objective: The aim of the current prospective study was
to analyse the validity of MRI based diagnosis of
brainstem gliomas which was verified by stereotactic
biopsy and follow-up evaluation as well as to assess
prognostic factors and risk profile.
Methods: Between 1998 and 2007, all consecutive adult
patients with radiologically suspected brainstem glioma
were included. The MRI based diagnosis of the lesions
was made independently by an experienced neuroradiol-
ogist. Histopathological evaluation was performed in all
patients from paraffin embedded specimens obtained by
multimodal image guided stereotactic serial biopsy
technique. Histopathological results were compared with
prior radiological assessment. Length of survival was
estimated with the Kaplan–Meier method and prognostic
factors were calculated using the Cox model.
Results: 46 adult patients were included. Histological
evaluation revealed pilocytic astrocytoma (n = 2), WHO
grade II glioma (n = 14), malignant glioma (n = 12),
metastasis (n = 7), lymphoma (n = 5), cavernoma
(n = 1), inflammatory disease (n = 2) or no tumour/
gliosis (n = 3). Perioperative morbidity was 2.5% (n = 1).
There was no permanent morbidity and no mortality. All
patients with ‘‘no tumour’’ or ‘‘inflammatory disease’’
survived. Patients with low grade glioma and malignant
glioma showed a 1 year survival rate of 75% and 25%,
respectively; the 1 year survival rate for patients with
lymphoma or metastasis was 30%. In the subgroup with a
verified brainstem glioma, negative predictors for length of
survival were higher tumour grade (p = 0.002) and
Karnofsky performance score (70 (p = 0.004).
Conclusion: Intra-axial brainstem lesions with a radio-
logical pattern of glioma represent a very heterogeneous
tumour group with completely different outcomes.
Radiological features alone are not reliable for diagnostic
classification. Stereotactic biopsy is a safe method to
obtain a valid tissue diagnosis, which is indispensible for
treatment decision.
Intra-axial brainstem gliomas in adults represent
approximately 2% of all brain tumours.1 In
children, the proportion of these tumour is as high
as 20–25%.1 2 Several reports have dealt with
brainstem gliomas in children in terms of their
biological behaviour, MRI findings, prognostic
factors and management.3–9
In contrast, features and biology of brainstem
gliomas in adults are less well known. Only a few
reports have focused on this tumour entity with only
one recent publication.10 In most of these studies,
treatment decisions were based on MRI features
alone and did not include a histopathological
diagnosis. Most authors regard a biopsy of intrinsic
brainstem tumours as too dangerous11–13 and consider
imaging methods as sufficiently reliable.14 Thus the
impact of MRI findings on treatment decisions for
brainstem tumours is very high but the accuracy of
MRI based diagnosis of brainstem gliomas has not to
date been verified sufficiently by histopathological
findings.
In the current literature, brainstem gliomas are
differentiated by MRI characteristics into two
subgroups: (a) focal tumours, which are typically
well marginated on MRI, occupy less than 50% of
the axial diameter of the brainstem and frequently
show contrast enhancement. These tumours are
usually regarded as low grade tumours and have a
good prognosis; and (b) diffuse brainstem tumours,
which are poorly marginated, rarely enhance with
contrast and occupy more than 50% of the axial
diameter of the brainstem. While the first group is
normally interpreted as pilocytic glioma with a
rather benign biology, the latter are mostly
considered malignant gliomas.14
The aim of this prospective study was to analyse
and validate the accuracy of conventional MRI
based classifications of brainstem gliomas. This
was achieved by comparing radiological diagnosis
with histopathological findings. In this context, we
also assessed risk profile as well as diagnostic and
prognostic relevance of a tissue diagnosis obtained
by stereotactic biopsy in patients with brainstem
lesions. For evaluation of prognostic factors, length
of survival was correlated with the obtained tissue
diagnosis and all relevant pretreatment clinical and
neuroradiological parameters.
CLINICAL MATERIAL AND METHODS
Patients
Between April 1998 and September 2007, all
consecutive adult patients were included in this
study if the epicentre of a suspected glioma was
located in the brainstem. Patients with radiological
and clinical evidence of disease other than glioma
were excluded. MRI was evaluated with a lesion
being suspicious of brainstem glioma (high or low
grade) in all patients enrolled.
MRI based assessment and diagnosis was per-
formed independently by an experienced neuro-
radiologist (MH) twice, with and without
knowledge of the clinical data (except for histol-
ogy). According to current radiological guidelines, a
brainstem glioma was defined by location of the
lesion (ie, mesencephalon, pons, medulla oblon-
gata) on imaging data (axial and sagittal T2 and T1
weighted images (with and without gadolinium)),
Research paper
1134 J Neurol Neurosurg Psychiatry 2009;80:1134–1139. doi:10.1136/jnnp.2009.174250
 group.bmj.com on July 4, 2013 - Published by jnnp.bmj.comDownloaded from 
performed with a 1.5 T scanner (Magnetom Vision; Siemens,
Erlangen, Germany). Tumours were assessed according to
current guidelines15 and distinguished as being focal (suspected
low grade) or diffuse (suspected high grade). They were judged
focal when they were well marginated, showing contrast
enhancement and occupying less than 50% of the axial
brainstem diameter. Poorly marginated tumours, with an
extension of more than 50% of brainstem diameter, were
classified as diffuse. The lesion was considered extended if it
involved more than one segment of the brainstem (eg, medulla
oblongata, pons).
For histological proof of diagnosis of brainstem glioma, all
patients underwent stereotactic biopsy. MRI/CT guided stereo-
tactic biopsy was performed as described previously.16 A
modified Riechert Stereotaxy System (MHT, Freiburg,
Germany) was used. Target definition for the biopsy procedure
was based on MRI. CT and MRI images were fused on a Brain
Lab work station. (Brain Lab image fusion software; Brain Lab,
Heimstetten, Germany) A 6 mm Burr whole was made and
serial biopsies along an exactly defined trajectory representative
of the area of interest were taken using micro forceps. The
average amount of tissue per biopsy specimen was 1 mm3 and
the number of specimens taken in 1 mm steps ranged from 5 to
15 samples per patient. Smear preparations of the biopsy
specimens were examined intraoperatively by an attending
neuropathologist in all patients. After the neuropathologist’s
statement that the amount of specimen was sufficient for
assessment, the biopsy procedure was stopped. The final
diagnosis was made from paraffin embedded tissue specimens
and the smear preparations (JH). Additional immunohisto-
chemical examination and an assessment of the proliferation
index were used.
For immediate follow-up, each patient (a) received a CT scan
postoperatively, which was assessed by a neuroradiologist to
confirm stereotaxy marker position and exclude haemorrhage
and (b) was examined clinically by a neurosurgeon for detection
of procedure related symptoms. Clinical follow-up was in
3 month intervals with a minimum follow-up of 1 year for all
patients. If patients did not attend for follow-up, the necessary
information was obtained by phone interview. Median follow-
up time for survivors was 33 months.
Treatment was initiated according to current recommenda-
tions and standards: radiotherapy for low grade gliomas and
lymphomas, radiochemotherapy for high grade gliomas, radio-
surgery for singular metastasis, antibiotic treatment for abscess,
immunosuppression for autoimmune inflammatory disease and
no treatment (observation) for no tumour/gliosis.
Sensitivity and specificity of conventional MRI imaging for
diagnosis of brainstem gliomas was estimated by comparison
with histological results.
Statistical analysis
Length of survival was estimated using the Kaplan–Meier
method. The impact of pretreatment factors on survival was
analysed using the Cox model.
RESULTS
Patient population
Between April 1998 and September 2007, 46 patients were
included (25 men, 21 women). All patients were adults
(.18 years). Age ranged from 18 to 78 years (median 43 years).
Median follow-up was 17 months (range 1 month to
91 months) (table 1). Clinical signs included ataxia (n = 30),
cranial nerve deficit (n = 27) and hemiparesis (n = 19).
Surgical procedure and complications
Three patients received a second biopsy (because of non-
pathological findings after the first procedure) and thus 49
procedures were performed. The surgical approach was frontal
extraventricular in 41 cases and suboccipital transpeduncular in
eight cases. There were two procedure related complications
(4%): in one patient a transient wound healing disorder
occurred which required no further surgical intervention. One
patient showed postoperative aggravation of a preoperatively
existing ataxia. There were no permanent complications. No
patient showed haemorrhage on postoperative CT scan.
Histopathological results
Histological evaluation revealed pilocytic astrocytoma (n = 2),
WHO grade II glioma (n = 14), malignant glioma (n = 12),
metastasis (n = 7), lymphoma (n = 5) (eg, see fig 1), cavernoma
(n = 1), inflammatory abscess (n = 1) and an inflammatory
demyelinising disease (n = 1). The diagnosis no tumour/gliosis
was achieved in three patients (table 2). In this three cases, the
stereotactic biopsy was repeated and showed an identical result.
Correlation of histological and radiological findings
Neuroradiological assessment as glioma differed from histo-
pathological diagnosis in 14 of 46 patients. In the subgroup of
patients with low grade gliomas (glioma grades I+II), the
specificity of MRI was 46.6% and sensitivity was 62.5%
(table 3). In the subgroup of patients harbouring glioma grade
III or IV, the specificity of MRI was 61.7% and sensitivity was
58.3% (table 4).
For tumour grading, radiological assessments were correct in
7/20 (35%) for low grade and in 7/26 (27%) for high grade
glioma.
Pathologies different from glioma showed much variety,
ranging from other neoplastic diseases (lymphoma (n = 5),
metastasis (n = 7)) to benign lesions (cavernoma (n = 1), no
tumour/gliosis (n = 3)) to inflammatory disease (encephalitis
disseminata, abscess (n = 2)) (table 2).
Follow-up/length of survival
All patients with no tumour/gliosis, inflammatory disease or
pilocytic astrocytoma survived the entire period of observation
or at least >1 year. Patients with WHO grade II glioma showed
a 1 year survival rate of 93% while this rate was 42% in patients
with malignant glioma (fig 2). Patients with lymphoma or
metastasis had a 1 year survival rate of 33%.
Negative predictors for length of survival in patients with
verified brainstem gliomas were higher tumour grade (p = 0.002)
and Karnofsky performance score (KPS) (p = 0.004). Age, duration
of symptoms, cranial nerve impairment, level of the tumour,
Table 1 Baseline characteristics of the patients enrolled
in the study
Characteristic No
Age (years) 43 (18–78)
Sex (M/F) 25/21
Duration of symptoms (weeks) 40 (1–360)
Survival (months) 28 (1–91)
Follow-up (months) 17 (1–91)
Values are median (range) or number.
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Figure 1 A 66-year-old female.
Symptoms developed within 3 weeks:
hemiparesis, hemihypesthesia, facial
palsy and vertigo. MRI showed contrast
enhancing lesion on T1 weighted (A, B)
and diffuse hyperintense lesion on T2
weighted (C) images. Histological workup
revealed a high cellular density
(haematoxylin–eosin (HE)) (D), a high
proliferation index (E) and strong
immunoreactivity for CD79a (F).
Histopathological diagnosis was B cell
lymphoma.
Table 2 Radiologically suspected brainstem glioma
(WHO Iu–IVu)
Histology No
Pilocytic astrocytoma (WHO Iu) 2
Low grade astrocytoma (WHO IIu) 14
Anaplastic astrocytoma (WHO IIIu) 8
Glioblastoma multiforme (WHO IVu) 4
Metastasis 7
Lymphoma 5
Inflammation 2
Cavernoma 1
No tumour/gliosis 3
Histological results in 46 patients with radiologically suspected
‘‘glioma’’ in the brainstem. In 28/46 patients, radiological diagnosis
was confirmed by histology.
Table 3 Radiologically suspected low grade gliomas
(WHO Iu and IIu)
Histology No
Pilocytic astrocytoma 1
Low grade astrocytoma IIu 6
Anaplastic astrocytoma IIIu 4
Glioblastoma multiforme 3
Lymphoma 2
Inflammation 2
No tumour/gliosis 1
Cavernoma 1
Metastasis 6
Histological diagnosis in the subgroup of patients with suspected
low grade glioma. In seven of 26 patients, tissue diagnosis met
radiological assessment.
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multifocal extension, tumour delineation and contrast enhance-
ment had no significant influence on length of survival (table 5).
Multivariate analysis was not performed because of shortage of
events.
DISCUSSION
In the present prospective study, we analysed the diagnostic value
of conventional MRI based diagnosis for assessment of presumed
intra-axial brainstem gliomas in an adult population by compar-
ison with histopathological diagnosis. In this context, we further
analysed the risk profile for stereotactic brainstem biopsies and
identified prognostic factors for survival in these patients.
The diagnostic management of patients with brainstem
tumours is controversial. Most authors rely on MR imaging
for treatment decisions as radiological findings are considered to
be sufficiently characteristic and specific.14 Thus histological
diagnosis is not warranted in most studies as biopsy of
brainstem lesions is considered to be a high risk procedure.11–13
In this study, patients were enrolled whose MRI images
showed suspected brainstem glioma according to established
features.14 15 Other brainstem lesions, which appeared radiolo-
gically untypical for gliomas, were not included in this
prospective investigation.
Diagnostic accuracy
Biopsy of those lesions thought to be gliomas revealed a
histopathological diagnosis different from the radiological
assessment in 18 of 46 cases by means of differentiating gliomas
from non-gliomas. This included two patients where the lesion
was found to be of an inflammatory nature (with negative CSF
parameters). In seven cases, metastasis of so far unknown origin
was found instead of a glioma. In five patients, lymphoma was
diagnosed as was a cavernoma in one patient. Three patients
showed no tumour or inflammatory tissue but only reactive
gliotic tissue, possibly linking to previous inflammatory of
vascular incidents. Thus radiological assessment misleadingly
classified some potential benign findings as gliomas.
Considering the completely different treatment options for
low grade glioma (brachytherapy, radiotherapy), high grade
glioma (radiotherapy, chemotherapy), abscess (draining, intra-
venous antibiotics) and inflammatory lesion (immunosuppres-
sion, immunomodulation), the percentage of incorrect
radiological diagnoses based on established features is extremely
high. Thus incorrect treatment decisions in these patients may
have fatal consequences or at least unnecessary strain.
In the group of radiological high grade gliomas, only seven of 20
patients had a glioma grade III or IVu while 10 patients had low
grade (grade I or II) glioma, lymphoma or metastasis. With regard
to the therapeutic consequence of radiotherapy or radiochem-
otherapy, these patients might have gained some benefit from
treatment but for two patients with no histological evidence of a
tumour, this treatment based on the radiological diagnosis might
have had severe consequences. A similar set was observed in the
group of suspected low grade gliomas, where two of 26 patients
showed inflammatory disease. Regarding this high number of
incorrect classifications of brainstem lesions by radiological means
and the necessity for highly specific therapies for the different
pathological entities, MRI alone should not be used for treatment
decisions, in our opinion.
In this study, all patients had a clear radiological diagnosis of
a brainstem glioma. Even then, within this supposedly
homogeneous group, this diagnosis was found to be incorrect
in 60% of cases (eg, see fig 1). For suspected low grade gliomas,
MRI specificity was as low as 46.6%; for malignant gliomas it
reached 61.7%. However, we cannot exclude the fact that the
explanatory power of these numbers might have been increased
by the involvement of a second independent neuroradiologist.
Our findings may be interpreted as being in contrast with
other studies published. Schumacher et al described a series of
Table 4 Radiologically suspected high grade gliomas
(WHO IIIu and IVu)
Histology No
Pilocytic astrocytoma (WHO Iu) 1
Low grade astrocytoma (WHO IIu) 6
Anaplastic astrocytoma (WHO IIIu) 5
Glioblastoma multiforme (WHO IVu) 2
Lymphoma 3
No tumour/gliosis 2
Metastasis 1
Histological diagnosis in the subgroup of patients with radiologically
suspected high grade glioma. Seven of 20 patients showed high
grade glioma in the histological workup.
Figure 2 Survival curve for study
cohort. Kaplan–Meier was estimated for
46 patients within a 95% two sided
confidence interval.
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142 paediatric cases with brainstem lesions, reporting a correct
classification by the radiologist in up to 90%.17 This may be due
to the paediatric patient population in this study where a
different frequency for various tumours is prevalent compared
with adults. Furthermore, lesions such as metastasis, lymphoma
or encephalitis disseminata are extremely rare in children and
thus the histological variety of brainstem lesions is larger in
adults, with important differences for therapeutic decisions.
For adult patient populations there are no recent studies
comparing MRI findings with histological diagnosis in brainstem
gliomas. The data of Kesari and colleagues10 include a high number
of patients with brainstem tumours but histological data are
provided for only 53%. A recent study by Salmaggi and colleagues18
included 32 patients with histopathology data in 21. Thus we have
provided reliable data focusing on the accuracy of conventional
MRI in the diagnosis of brainstem gliomas for the first time.
New imaging technologies such as MR spectroscopy and
positron emission tomography have been proved to be useful
tools for assessing supratentorial gliomas19–21 and may improve
the non-invasive diagnosis of brainstem gliomas also, but
prospective data regarding the accuracy of these methods in
this subset of tumours are pending.
It should be noted that radiological assessment, even with
inclusion of further imaging techniques, is subject to an
individual range of interpretation, which is not only based on
experience but also influenced by the amount of available
additional information for the radiologist; a fact which also
applies—to a lesser extent—to pathologists’ assessment. Thus
in the light of both the variety of pathologies frequently
demanding specific treatment strategies and the justifiable
procedure related risk, maximal yield of diagnostic information,
including stereotactic biopsy, should be pursued.
Of further importance is the upcoming role of molecular
markers in glioma therapy.22–26 As an example, in the treatment
of malignant gliomas, MGMT promoter methylation has a
growing impact on treatment decisions, as well as other
molecules (eg, integrins). Although clinical data for brainstem
gliomas and the impact of MGMT on treatment response are
pending, the influence of molecular markers on treatment
decisions might be significant and will require tissue diagnosis.
Risk profile
Although several authors showed a large variety of histological
results in brainstem masses by brainstem biopsy,27–29 the indica-
tion for this procedure is still a matter of debate. Even in the most
recent study by Kesari et al with a high number of patients,
histological diagnosis was obtained in only 53% of cases.10 Many
authors claim a very restrictive indication for radiologically
unclear lesions because of the presumed high risk profile.
In some published studies, a high number of complications by
stereotactic brainstem biopsies occurred, reaching up to 10%.11–13
As a consequence, the authors of these studies propagated a
non-invasive approach.12–14 Previous studies from our institution
have proved that stereotactic biopsy is a safe and reliable
method with a high diagnostic yield.30 31 In this present study,
there were no major procedure related complications in spite of
the highly eloquent target localisation. Apart from one wound
healing disorder, only one patient showed a slight deterioration
of a preoperatively existing ataxia, which recovered slowly
during the following months. There were no procedure related
bleedings. The extremely low incidence of complications in the
present study may be attributed to a very high number of
stereotactic biopsies per year at the authors’ institution and a
highly standardised workflow. Thus our numbers may not
reflect the actual risk profile at centres with less experience of
stereotactic procedures.
The diagnostic results obtained by biopsy were conclusive
with follow-up data. Three patients with no pathological
findings in the first biopsy underwent re-biopsy with an
identical histological pattern. The natural course of these
patients underlines the absence of a tumour or inflammatory
disease and thus confirmed the histological diagnosis.
Comparing the reported procedure related risk of a stereo-
tactic biopsy in suspected brainstem glioma with the probability
of an incorrect radiological diagnosis and its therapeutic
consequences, biopsy not only is justifiable but should be
pursued in these patients, in our opinion.
Nevertheless, brainstem lesions are comparatively rare find-
ings. Thus a successful and safe biopsy in brainstem regions
requires a high technical infrastructure, an experienced stereo-
tactic neurosurgeon and a highly standardised workflow for
these procedures. Thus biopsies in these eloquent areas should
be performed in specialised centres.
Prognostic factors for survival
There are few current data dealing with the prognosis and
prognostic factors in brainstem gliomas in adults.10 32 This may
be because of the low incidence of these tumours and rarely
confirmed histopathological diagnosis. In our series, only
tumour grade (p = 0.002) and KPS (p = 0.004) reached statistical
significance. In the most recent study by Kesari and colleagues,10
a large series of brainstem tumours in adults was evaluated
retrospectively with regard to prognostic factors. In Kesari’s series
several other parameters (eg, age and duration of symptoms) also
reached statistical significance. Furthermore, survival rate for low
grade gliomas in his study was significantly larger than in our
series. However, in Kesari’s study, histological diagnosis was
obtained in only 54 of 101 patients. Considering the limited
diagnostic accuracy of MRI for glioma diagnosis, these data may
be influenced by a certain number of non-glioma lesions which we
have shown to have a completely different natural course.
CONCLUSION
The diagnostic value of conventional MRI imaging in treatment
planning of brainstem gliomas in adults is insufficient. Tissue
diagnosis is mandatory for adequate treatment decision.
Multimodally guided stereotactic biopsy of brainstem gliomas
is a low risk procedure with a high diagnostic value in
experienced hands and thus should be regarded as standard in
adult patients with brainstem lesions.
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Table 5 Univariate analysis of survival
Candidate covariates
Univariate
p value
Diffuse growth pattern 0.96
Extension .1 segment 0.43
Higher tumour grade 0.002*
Age 0.15
Duration of symptoms 0.39
Contrast enhancement 0.21
Karnofsky performance score 0.004*
Cranial nerve impairment 0.85
In univariate analysis, two prognostic factors (*) reached statistical
significance for influence on survival.
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